Compugen to Present AI/ML Driven Predictive Computational Research at Upcoming International Scientific Conferences

HOLON, ISRAEL, June 12, 2025 - Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the presentation of AI/ML driven predictive computational research at upcoming international scientific conferences reflecting Compugen's scientific capabilities in understanding complex cancer biology.

Poster details:

Conference: 2025 Annual Congress of the European Association for Cancer Research, June 16-19 Lisbon, Portugal
Poster number: EACR25-3113
Tite: Prediction of immune evasion and immunotherapy resistance mechanisms associated with distinct TNBC subtypes
Presenting author: Amir Toporik, Computational Discovery, Compugen
Date of presentation: June 18, 2025

Conference: International Society for Computational Biology and European Conference on Computational Biology- Annual International Conference on Intelligent Systems for Molecular Biology, July 20-24, 2025, Liverpool, UK
Poster number: 947
Title: Computational prediction of TNBC tumor subtypes from an integrative single cell atlas elucidates immune evasion and immunotherapy resistance mechanisms
Presenting author: Itamar Borukhov, Ph.D., Computational Discovery, Compugen

Posters will be available in the publications section of Compugen's website, www.cgen.com, following presentation.

About Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery platform (Unigen™) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. GS-0321

(previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which is in Phase 1 development is licensed to Gilead. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of research programs aiming to address various mechanisms to enhance anti-cancer immunity. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

Company contact:
Yvonne Naughton, Ph.D.
Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071